Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 4/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | FCER2 | P06734 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21661227 | 1.00 | ECE1 (0.41) | ECE1NOD1ACECNR2MME | |
| SCHEMBL29531850 | 0.83 | NOD1 (0.39) | ECE1NOD1ACEMMECA1 | |
| SCHEMBL4254687 | 0.82 | ECE1 (0.38) | ECE1NOD1ACEMMEENPEP | |
| SCHEMBL12112075 | 0.81 | ECE1 (0.60) | ECE1NOD1ACEENPEPMMP1 | |
| SCHEMBL22623434 | 0.81 | ALDH1A1 (0.44) | ECE1CNR2MMECA1MMP1 | |
| SCHEMBL24915226 | 0.81 | ALDH1A1 (0.44) | ECE1CNR2MMECA1MMP1 | |
| SCHEMBL14268997 | 0.81 | ALDH1A1 (0.44) | ECE1CNR2MMECA1MMP1 | |
| SCHEMBL25444868 | 0.80 | MME (0.49) | ECE1ACEMMECPA1ACE2 | |
| SCHEMBL16327960 | 0.80 | MME (0.49) | ECE1ACEMMECPA1ACE2 | |
| SCHEMBL19295555 | 0.80 | MME (0.49) | ECE1ACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | ECE1 3280/4885NOD1 23/4885ACE 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.